Insider Buying: CorMedix (NASDAQ:CRMD) CEO Purchases 80,000 Shares of Company Stock

CorMedix Inc (NASDAQ:CRMD – Get Free Report) CEO Joseph Todisco bought 80,000 shares of CorMedix stock in a transaction that occurred on Friday, November 13th. The stock was purchased at an average price of $4.89 per share, for a total transaction of $391,200.00. Following the acquisition, the chief executive officer directly owned 854,749 shares of the company’s stock, valued at $4,179,722.61. The trade was a 10.33% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

CorMedix Price Performance

CRMD stock opened at $4.66 on Monday. The stock has a 50-day moving average price of $7.18 and a two-hundred day moving average price of $7.57. CorMedix Inc has a 12-month low of $4.65 and a 12-month high of $13.02. The company has a current ratio of 2.56, a quick ratio of 2.36 and a debt-to-equity ratio of 0.31. The company has a market cap of $363.22 million, a PE ratio of 6.75, a price-to-earnings-growth ratio of 0.90 and a beta of 1.48.

CorMedix (NASDAQ:CRMD – Get Free Report) last released its quarterly earnings data on Thursday, November 12th. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.07). The firm had revenue of $54.52 million during the quarter, compared to analysts’ expectations of $51.76 million. CorMedix had a return on equity of 27.12% and a net margin of 15.49%. As a group, research analysts predict that CorMedix Inc will post 0.52 EPS for the current year.

Analyst Ratings Changes

CRMD has been the topic of several research reports. Needham & Company LLC raised their price target on shares of CorMedix from $12.00 to $14.00 and gave the company a “buy” rating in a report on Tuesday, November 10th. Oppenheimer reiterated an “outperform” rating and set a $13.00 price objective (down from $15.00) on shares of CorMedix in a research note on Friday. Citigroup reaffirmed a “market outperform” rating on shares of CorMedix in a research report on Tuesday, November 10th. Weiss Ratings lowered CorMedix from a “hold (c+)” rating to a “hold (c)” rating in a research report on Tuesday, November 10th. Finally, Royal Bank Of Canada raised their target price on CorMedix from $14.00 to $15.00 and gave the company an “outperform” rating in a research note on Tuesday, November 10th. Eight research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, CorMedix has a consensus rating of “Moderate Buy” and a consensus price target of $15.22.

Get Our Latest Report on CorMedix

Institutional Investors Weigh In On CorMedix

Several large investors have recently made changes to their positions in CRMD. BlackRock Inc. bought a new stake in shares of CorMedix during the second quarter valued at about $49,644,000. Marshall Wace LLP grew its position in CorMedix by 53.4% in the 3rd quarter. Marshall Wace LLP now owns 1,195,422 shares of the company’s stock valued at $9,205,000 after buying an additional 415,887 shares in the last quarter. Pacer Advisors Inc. grew its position in CorMedix by 128.7% in the 1st quarter. Pacer Advisors Inc. now owns 580,620 shares of the company’s stock valued at $3,942,000 after buying an additional 326,724 shares in the last quarter. Hennion & Walsh Asset Management Inc. increased its stake in CorMedix by 150.6% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 438,629 shares of the company’s stock valued at $3,443,000 after buying an additional 263,618 shares during the period. Finally, Bank of New York Mellon Corp acquired a new position in CorMedix during the 2nd quarter valued at about $3,108,000. Institutional investors and hedge funds own 34.18% of the company’s stock.

CorMedix Company Profile

(Get Free Report)

CorMedix Inc. is a biopharmaceutical company focused on products for infectious and inflammatory diseases. Its lead product, DefenCath, is an antimicrobial catheter-lock solution containing taurolidine and heparin. The U.S. Food and Drug Administration approved it to reduce catheter-related bloodstream infections in adults with kidney failure who receive chronic hemodialysis through a central venous catheter. CorMedix expanded its business in 2024 by acquiring Melinta Therapeutics, adding marketed antibiotics to its portfolio.

Recommended Stories

Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.